Latest News
SELLAS Stock Surges as REGAL Trial Nears Final Analysis
SELLAS Life Sciences shares rose after hours as its REGAL leukemia trial recorded 78 of 80 events needed for final analysis. The company reported a Q1 net loss of $8.4 million but has $107.1 million in cash.
BAT Shares Surge on FDA Policy Shift and Legal Resolution
British American Tobacco shares rose 5.82% in London after the FDA signaled a softer stance on e-cigarette enforcement and a U.S. judge dismissed a North Korea sanctions case.
Oscar Health Shares Surge as Focus Shifts to Margin Strength
Oscar Health shares rose 7.9% to $23.73 late Tuesday as investors prioritized strong profit margins over a Q1 revenue miss, with the medical loss ratio improving to 70.5%.
Zebra Technologies Surges on Strong Q1 Results and Upgraded Forecast
Shares of Zebra Technologies climbed 11.5% after Q1 earnings beat estimates and the company raised its full-year guidance, pointing to a rebound in automation demand.
Ernexa Therapeutics Soars 58% on Ovarian Cancer Therapy Hopes
Ernexa Therapeutics surged 58.5% on Tuesday after renewed investor interest in its preclinical ovarian-cancer cell therapy ERNA-101, though funding concerns persist.
UnitedHealth Shares Surge as Investors Bet on Recovery, PBM Reform
UnitedHealth shares climbed 3.1% as the company unveiled a new Optum Rx fee-based pricing model and raised 2026 profit guidance, signaling a potential turnaround.
Byron Allen's $120M Bet Revives BuzzFeed Stock, But Turnaround Uncertain
BuzzFeed shares nearly doubled after Byron Allen's family office agreed to buy a controlling stake, but the deal is mostly debt and the company still faces a going concern warning.
Dow Holds Steady at 49,700 as Inflation Data Rattles Tech and Rate Outlook
The Dow ended nearly unchanged at 49,700.29, but the S&P 500 dropped 0.54% and the Nasdaq fell 1.37% after April CPI surged 3.8%, driven by energy costs.
ZoomInfo Plunges 35% on AI Disruption, Cuts 2026 Revenue Forecast
ZoomInfo shares tumbled 35% Tuesday after the company slashed its 2026 revenue forecast to $1.185-1.205 billion, citing AI-related buying pauses and pricing pressure.